Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 5 (May)

1. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer.
   Obstet Gynecol, 109(5): 1053-61. [Abstract] [Full-text]
2. Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer.
   Clin Genet, 71(4): 331-42. [Abstract] [Full-text]
3. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway.
   Clin Cancer Res, 13(9): 2777-83. [Abstract] [Full-text]
4. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
   BMC Cancer, 7: 65. [Abstract] [Full-text]
5. Malnutrition among gynaecological cancer patients.
   Eur J Clin Nutr, 61(5): 642-6. [Abstract] [Full-text]
6. Predictors of comprehensive surgical treatment in patients with ovarian cancer.
   Cancer, 109(10): 2031-42. [Abstract] [Full-text]
7. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
   Oncogene, 26(20): 2894-901. [Abstract] [Full-text]
8. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
   Oncogene, 26(20): 2860-72. [Abstract] [Full-text]
9. BRAF T1799A mutation occurring in a case of malignant struma ovarii.
   Int J Surg Pathol, 15(2): 116-20. [Abstract] [Full-text]
10. Ovarian capillary hemangioma presenting as pseudo-Meigs' syndrome: a case report.
    J Minim Invasive Gynecol, 14(3): 367-9. [Abstract] [Full-text]
11. Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery.
    J Minim Invasive Gynecol, 14(3): 352-5. [Abstract] [Full-text]
12. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Cancer Res, 67(9): 4474-81. [Abstract] [Full-text]
13. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
    Cancer Lett, 251(2): 247-57. [Abstract] [Full-text]
14. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    Histopathology, 50(6): 773-9. [Abstract] [Full-text]
15. Ovarian epithelial carcinoma with estrogen-producing stroma.
    Pathol Int, 57(5): 285-90. [Abstract] [Full-text]
16. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.
    Cancer, 109(8): 1513-22. [Abstract] [Full-text]
17. Disappearance of a stutter shortly before death.
    Am J Hosp Palliat Care, 24(2): 141-3. [Abstract] [Full-text]
18. Excision of large cystic ovarian tumors: combining minimal invasive surgery techniques and cancer surgery--the best of both worlds.
    J Pediatr Surg, 42(5): 890-3. [Abstract] [Full-text]
19. Laparoscopic ovarian tissue preservation in young patients at risk for ovarian failure as a result of chemotherapy/irradiation for primary malignancy.
    J Pediatr Surg, 42(5): 862-4. [Abstract] [Full-text]
20. Heparan sulphate synthetic and editing enzymes in ovarian cancer.
    Br J Cancer, 96(10): 1544-8. [Abstract] [Full-text]
21. Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus.
    Br J Cancer, 96(10): 1613-20. [Abstract] [Full-text]
22. Quality of life of Chinese patients with ovarian malignancies during chemotherapy under condition of no recurrence.
    Cancer Nurs, 30(3): 243-51. [Abstract] [Full-text]
23. The ovarian cancer journey of families the first postdiagnostic year.
    Cancer Nurs, 30(3): 232-42. [Abstract] [Full-text]
24. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
    Cancer Res, 67(10): 5003-8. [Abstract] [Full-text]
25. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
    Cancer Res, 67(10): 4924-32. [Abstract] [Full-text]
26. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
    Cancer Res, 67(10): 4843-50. [Abstract] [Full-text]
27. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.
    Cancer Res, 67(10): 4783-9. [Abstract] [Full-text]
28. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.
    Mol Cancer Res, 5(5): 413-21. [Abstract] [Full-text]
29. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.
    Hum Pathol, 38(6): 926-34. [Abstract] [Full-text]
30. Ovarian conservation at the time of hysterectomy for benign disease.
    Clin Obstet Gynecol, 50(2): 354-61. [Abstract] [Full-text]
31. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
    J Clin Oncol, 25(15): 2049-56. [Abstract] [Full-text]
32. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
    J Clin Oncol, 25(15): 2042-8. [Abstract] [Full-text]
33. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    J Clin Oncol, 25(15): 2027-34. [Abstract] [Full-text]
34. Ovarian cancer and hormone replacement therapy in the Million Women Study.
    Lancet, 369(9574): 1703-10. [Abstract] [Full-text]
35. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Gynecol Oncol, 105(3): 769-75. [Abstract] [Full-text]
36. Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian cancer genes.
    PLoS Comput Biol, 3(4): e72. [Abstract] [Full-text]
37. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gynecol Oncol, 105(3): 780-3. [Abstract] [Full-text]
38. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.
    Gynecol Oncol, 105(3): 801-12. [Abstract] [Full-text]
39. Demons syndrome revisited: a review of the literature.
    Gynecol Oncol, 105(3): 796-800. [Abstract] [Full-text]
40. The role of cytoreductive surgery for colon cancer metastatic to the ovary.
    Gynecol Oncol, 105(3): 791-5. [Abstract] [Full-text]
41. Venous thromboembolism in ovarian cancer.
    Gynecol Oncol, 105(3): 784-90. [Abstract] [Full-text]
42. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Gynecol Oncol, 105(3): 712-5. [Abstract] [Full-text]
43. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
    Gynecol Oncol, 105(3): 657-61. [Abstract] [Full-text]
44. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma.
    Gynecol Oncol, 105(3): 762-8. [Abstract] [Full-text]
45. Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.
    Gynecol Oncol, 105(3): 716-21. [Abstract] [Full-text]
46. Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition.
    Gynecol Oncol, 105(3): 703-11. [Abstract] [Full-text]
47. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
    Gynecol Oncol, 105(3): 695-702. [Abstract] [Full-text]
48. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    Gynecol Oncol, 105(3): 667-71. [Abstract] [Full-text]
49. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Gynecol Oncol, 105(3): 747-56. [Abstract] [Full-text]
50. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study.
    Gynecol Oncol, 105(3): 687-94. [Abstract] [Full-text]
51. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
    Gynecol Oncol, 105(3): 586-92. [Abstract] [Full-text]
52. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Gynecol Oncol, 105(3): 578-85. [Abstract] [Full-text]
53. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer.
    Gynecol Oncol, 105(3): 604-8. [Abstract] [Full-text]
54. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Gynecol Oncol, 105(3): 625-9. [Abstract] [Full-text]
55. Validation of tissue microarray technology in endometrioid cancer of the endometrium.
    J Clin Pathol, 60(5): 500-3. [Abstract] [Full-text]
56. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.
    Clin Chem, 53(6): 1067-74. [Abstract] [Full-text]
57. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.
    Cancer, 109(9): 1887-96. [Abstract] [Full-text]
58. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Cancer, 109(9): 1784-90. [Abstract] [Full-text]
59. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.
    Int J Cancer, 121(2): 225-31. [Abstract] [Full-text]
60. The cytoskeletal proteins alpha-actinin, Ezrin, and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium.
    Appl Immunohistochem Mol Morphol, 15(2): 170-4. [Abstract] [Full-text]
61. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Am J Surg Pathol, 31(6): 854-69. [Abstract] [Full-text]
62. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
    Am J Surg Pathol, 31(6): 846-53. [Abstract] [Full-text]
63. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
    Br J Cancer, 96(11): 1639-43. [Abstract] [Full-text]
64. Cancer, cardiovascular disease and diabetes mortality among women with a history of endometrial cancer.
    Br J Cancer, 96(11): 1747-9. [Abstract] [Full-text]
65. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
    J Clin Oncol, 25(16): 2281-7. [Abstract] [Full-text]
66. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
    Int J Cancer, 121(3): 606-14. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.